Janux Therapeutics JANX Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Janux Therapeutics's deferred revenue?
- Janux Therapeutics (JANX) reported deferred revenue of $46.27M in Q1 2026.
- What is the long-term trend for Janux Therapeutics's deferred revenue?
- Over 3 years (2021 to 2025), Janux Therapeutics's deferred revenue has grown at a -100.0% compound annual growth rate (CAGR), from -$2.14M to $0.